Civica signs up Profil to run trials for affordable insulin biosimilars
Civica Rx has chosen Germany-based CRO Profil to run clinical trials for its “affordable insulin” candidates.
Civica Rx has chosen Germany-based CRO Profil to run clinical trials for its “affordable insulin” candidates.
Merck KGaA’s North American healthcare business, EMD Serono, is discontinuing a clinical trial for a med once considered a star in its oncology program, but an interim analysis has the company changing tactics.
A device that’s meant to clear out and expand the lungs may actually go too far, resulting in a potentially dangerous decrease in overall oxygen levels, Baxter said this week.
This could be good news, or bad news. Amylyx Pharmacueticals has received notice from the FDA that the decision date for its amyotrophic lateral sclerosis drug has been extended.
Qiming Venture Partners appears to be living up to its name—which translates to enlightened in Chinese—closing out an oversubscribed $260 million financing round and adding a former biotech CEO to its panel of partners that leads the company.
Russia’s assault on Ukraine is being felt worldwide, and the U.S. healthcare system is not immune.
Fresh off the FDA’s clearance for its latest continuous glucose monitor, the FreeStyle Libre 3, Abbott is already attempting to one-up itself.
BD will begin rolling out its latest technology for sorting and characterizing the myriad cells that make up the human body, with a speed and clarity that the company says could help identify new types of cells and the roles they play in life and disease.
Biogen is back with a fresh cut of data on its antisense amyotrophic lateral sclerosis (ALS) candidate, pooling the results of a failed phase 3 and an open-label extension in an attempt to find a way forward for the Ionis Pharmaceuticals-partnered prospect.
The FDA has no plans to make a decision on whether Aeglea BioTherapeutics’ rare disease drug is approvable, at least not until the company turns over clinical data that demonstrate a treatment effect.